adalimumab
Abbvie
['axspa', 'ibd']
at the 12-month mark, 52% of patients in the axspa cohort and 76% of those in the #ibd cohort receiving tnf treatment achieved clinical remission. learn more: #rheumatology #ddw2023
HCPLive Rheumatology provides clinically impactful news and updates for HCPs treating rheumatic disease.